The RNAseq data from the UKE ovarian cancer patient cohort showed that the expression of CD163 was correlated with other M2 markers, such as CD206 and CD204, and was also positively associated with the expression of TIGIT and TIM-3. This evidence concerns the gene CD163 and ovarian cancer.